Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evaxion Biotech ( (EVAX) ) just unveiled an update.
On April 16, 2026, Evaxion A/S held its Annual General Meeting, where shareholders representing 25.15% of outstanding ordinary shares approved the 2025 audited annual report and resolved that the year’s loss be carried forward. The meeting re-elected four directors, appointed Jens Bitsch-Nørhave as a new board member, and confirmed EY Godkendt Revisionspartnerselskab as auditor, reinforcing continuity in governance and oversight.
Shareholders also approved amendments to Evaxion’s Articles of Association to expand the board’s authority to issue up to DKK 11.9 million in warrants and to establish a new authorization to raise up to DKK 73.5 million via convertible loan notes, both without pre-emptive rights for existing shareholders. These changes, effective April 16, 2026, provide the company with greater flexibility to incentivize key personnel and access equity-linked financing, potentially supporting future growth but also opening the door to share dilution for current investors.
The most recent analyst rating on (EVAX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is driven primarily by improved capitalization but still-weak cash generation and profitability. Technicals are moderately favorable with improving momentum, while valuation remains limited by losses. Earnings-call commentary adds support via clear milestone roadmap, strong EVX-01 results, and runway into H2 2027, tempered by dilution/partnering execution risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S, which also operates under the names Evaxion Biotech A/S and NovVac A/S, is a Danish biotechnology company that develops advanced software to enable novel immunotherapies and vaccines. The company focuses on leveraging computational platforms to design immune-based treatments, positioning it within the AI-driven biopharmaceutical and vaccine development space.
Average Trading Volume: 42,063
Technical Sentiment Signal: Sell
Current Market Cap: $37.45M
Learn more about EVAX stock on TipRanks’ Stock Analysis page.